Literature DB >> 25470627

The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.

Hanaa M El-Karaksy1, Mona S El-Raziky2, Hanan M Fouad3, Ghada M Anwar2, Fatma M El-Mougy4, Nehal M El-Koofy2, Ahmad M El-Hennawy5.   

Abstract

OBJECTIVE: The aim of the present study was to determine the association between insulin resistance (IR) and both non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) in a group of Egyptian overweight/obese children and adolescents and to evaluate different IR indices in detection of NAFLD. PATIENTS AND METHODS: The study included 76 overweight/obese children aged 2-15 years; 52.6% were males. Laboratory analysis included fasting blood glucose, serum insulin, lipid profile, liver biochemical profile, and liver ultrasound. IR was calculated using the following indices; the homeostasis model assessment method (HOMA-IR), the quantitative insulin-sensitivity check index (QUICKI) and hepatic insulin sensitivity. The National Cholesterol Education Program Adult Treatment Panel III criteria were used to estimate prevalence of MetS. Liver biopsy was done when medically indicated and accepted by parents.
RESULTS: IR was detected in 43.4% and 34.2% by using QUICKI and HOMA, respectively. MetS was detected in 36.8% and NAFLD was detected in 45.5% among those performing liver biopsy. Cases with NAFLD had more frequent IR than children with normal histology. QUICKI showed significant difference between normal subjects and both steatosis and non-alcoholic steatohepatitis; while HOMA-IR was sensitive in cases with NASH only. MetS was present in 100% of patients with NASH and in 75% of those with steatosis and they were all obese. Patients with NASH had significantly higher ALT than those with normal histology.
CONCLUSION: IR was significantly associated with NAFLD. QUICKI is considered more sensitive than HOMA-IR in differentiating simple steatosis from normal liver histology.
Copyright © 2013 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Children; Insulin resistance; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity; Overweight

Mesh:

Substances:

Year:  2013        PMID: 25470627     DOI: 10.1016/j.dsx.2013.10.008

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  5 in total

1.  Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features.

Authors:  Everton Cazzo; Laísa Simakawa Jimenez; Martinho Antonio Gestic; Murillo Pimentel Utrini; Fábio Henrique Mendonça Chaim; Felipe David Mendonça Chaim; José Carlos Pareja; Elinton Adami Chaim
Journal:  Obes Surg       Date:  2018-01       Impact factor: 4.129

2.  Assessment of triglyceride and cholesterol in overweight people based on multiple linear regression and artificial intelligence model.

Authors:  Jing Ma; Jiong Yu; Guangshu Hao; Dan Wang; Yanni Sun; Jianxin Lu; Hongcui Cao; Feiyan Lin
Journal:  Lipids Health Dis       Date:  2017-02-20       Impact factor: 3.876

Review 3.  The Liver in Children With Metabolic Syndrome.

Authors:  Ebe D'Adamo; Valeria Castorani; Valerio Nobili
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

4.  Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2-hour plasma glucose in individuals without diabetes.

Authors:  Xuyi Wang; Chang Chen; Cong Xie; Weikun Huang; Richard L Young; Karen L Jones; Michael Horowitz; Christopher K Rayner; Zilin Sun; Tongzhi Wu
Journal:  Diabetes Obes Metab       Date:  2022-03-22       Impact factor: 6.408

Review 5.  Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System.

Authors:  Mohamed H Ahmed; Sufian K Noor; Sarra O Bushara; Nazik Elmalaika Husain; Wadie M Elmadhoun; Ibrahim A Ginawi; Meissa M Osman; Abdalhafeez O Mahmoud; Ahmed O Almobarak
Journal:  Gastroenterology Res       Date:  2017-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.